Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria

Q3 Medicine Allergo Journal International Pub Date : 2023-12-12 DOI:10.1007/s40629-023-00278-1

Adriano Fabi BMed, Stefan Milosavljevic MSc PhD, Claudia C. V. Lang MD, Carole Guillet MD, Peter Schmid-Grendelmeier MD

{"title":"Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria","authors":"Adriano Fabi BMed, Stefan Milosavljevic MSc PhD, Claudia C. V. Lang MD, Carole Guillet MD,  Peter Schmid-Grendelmeier MD","doi":"10.1007/s40629-023-00278-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Omalizumab is recommended as adjunctive therapy for antihistamine-refractory chronic spontaneous urticaria (CSU). However, its long-term effectiveness is understudied. The systemic immune-inflammation index (SII) and the systemic inflammatory response index (SIRI) have shown prognostic value in cancer, strokes, and other diseases.</p><h3>Objectives</h3><p>This study aimed to evaluate the long-term effectiveness of omalizumab in CSU patients while investigating potential associations of SII and SIRI with the drug survival of omalizumab.</p><h3>Methods</h3><p>A retrospective study was conducted using patient data from the electronic hospital database, including patients with CSU treated with omalizumab between January 2018 and May 2021. Drug survival curves were visualized using Kaplan-Meier survival analysis. and Cox regression was utilized to assess potential associations.</p><h3>Results</h3><p>A total of 109 CSU treated with omalizumab at the University Hospital of Zurich were included. The mean drug survival was 13.6 ± 10.9 months. The mean SII and SIRI were 796.1 ± 961.3 and 2.1 ± 3.1, respectively. The multivariate model revealed that SIRI (<i>p</i> = 0.098) was a more robust predictor of omalizumab’s drug survival than SII (<i>p</i> = 0.367), while concurrent autoimmune disease or baseline immunoglobulin E (IgE) levels showed no significant impact.</p><h3>Conclusion</h3><p>This study suggests the potential utility of SIRI as a superior predictive indicator for omalizumab’s drug survival in CSU patients compared to SII. Concomitant autoimmune disease or baseline IgE levels did not significantly affect the drug’s effectiveness.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00278-1.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-023-00278-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Omalizumab is recommended as adjunctive therapy for antihistamine-refractory chronic spontaneous urticaria (CSU). However, its long-term effectiveness is understudied. The systemic immune-inflammation index (SII) and the systemic inflammatory response index (SIRI) have shown prognostic value in cancer, strokes, and other diseases.

Objectives

This study aimed to evaluate the long-term effectiveness of omalizumab in CSU patients while investigating potential associations of SII and SIRI with the drug survival of omalizumab.

Methods

A retrospective study was conducted using patient data from the electronic hospital database, including patients with CSU treated with omalizumab between January 2018 and May 2021. Drug survival curves were visualized using Kaplan-Meier survival analysis. and Cox regression was utilized to assess potential associations.

Results

A total of 109 CSU treated with omalizumab at the University Hospital of Zurich were included. The mean drug survival was 13.6 ± 10.9 months. The mean SII and SIRI were 796.1 ± 961.3 and 2.1 ± 3.1, respectively. The multivariate model revealed that SIRI (p = 0.098) was a more robust predictor of omalizumab’s drug survival than SII (p = 0.367), while concurrent autoimmune disease or baseline immunoglobulin E (IgE) levels showed no significant impact.

Conclusion

This study suggests the potential utility of SIRI as a superior predictive indicator for omalizumab’s drug survival in CSU patients compared to SII. Concomitant autoimmune disease or baseline IgE levels did not significantly affect the drug’s effectiveness.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

慢性自发性荨麻疹患者全身免疫炎症指数和全身炎症反应指数对奥马珠单抗药物存活率的预测价值

背景奥马珠单抗被推荐作为抗组胺药难治性慢性自发性荨麻疹（CSU）的辅助疗法。然而，对其长期疗效的研究尚不充分。全身免疫炎症指数（SII）和全身炎症反应指数（SIRI）在癌症、中风和其他疾病中显示出预后价值。目的本研究旨在评估奥马珠单抗在CSU患者中的长期有效性，同时调查SII和SIRI与奥马珠单抗药物存活率的潜在关联。方法利用医院电子数据库中的患者数据进行了一项回顾性研究，包括2018年1月至2021年5月期间接受奥马珠单抗治疗的CSU患者。采用 Kaplan-Meier 生存分析对药物生存曲线进行可视化，并利用 Cox 回归评估潜在的关联。平均药物存活期为 13.6 ± 10.9 个月。平均 SII 和 SIRI 分别为 796.1 ± 961.3 和 2.1 ± 3.1。多变量模型显示，SIRI（p = 0.098）比 SII（p = 0.367）更能预测奥马珠单抗的药物存活率，而并发自身免疫性疾病或基线免疫球蛋白 E（IgE）水平则无显著影响。伴随的自身免疫性疾病或基线 IgE 水平对药物疗效没有明显影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Allergo Journal International Medicine-Immunology and Allergy

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies. All submissions are reviewed in single-blind fashion by at least two reviewers. Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.